ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jul 18, 2022 17:00 JST
Source:
Novotech Health Holdings Pte Ltd
Novotech and Endpoints Present "Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T"
SYDNEY, AU, Jul 18, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, is pleased to present an Endpoints webinar on CAR-T therapy in China - the current landscape and future opportunities.
China now represents 60% of clinical development in CAR-T therapy development globally. This webinar will cover learnings to date and future opportunities.
Specific areas covered include:
- The current landscape for biotech CAR-T therapy research in China
- CAR-T clinical development in China: key areas of focus
- Potential opportunities related to universal CAR-T cell therapy development
- The challenges of allogeneic CAR-T cell therapy
Register here:
https://webinars.endpts.com/evolution-of-cell-gene-therapy-in-china-the-case-for-universal-car-t/
Webinar Date:
- July 19, 2022
- 1:00 pm - 2:00 pm EDT
Moderator:
- Arsalan Arif, Founder and Publisher Endpoints News
Presenters:
- Dr. Jie Cheng, Chief Medical Officer Bioheng
- Dr. Vivian Gu, Vice President, Clinical Development & Regulatory, CMO, Novotech China
- Dr Kai Xue, Associate Professor, Department of Haematology, Ruijin Hospital, Shanghai, China
According to Global Data: "Over the last five years more than 70,000 new clinical trials were registered in the APAC region, the US, and the EU5. The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%). The APAC region has become the preferred destination for conducting clinical trials due to its large patient population, ease of regulatory compliance, lower cost of conducting studies, high-quality standards and the presence of top clinical sites."
Novotech CEO Dr. John Moller said: "The Asia-Pacific is the fastest-growing clinical trial destination for biotechs, with China being the leading location for new trials followed by the US. Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, also offers its biotech clients clinical services in the US to support later phase global studies. Novotech's service delivery model is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasises problem-solving, ownership and flexibility, and our investments in data and technology ensure clients have real-time access to trial performance."
Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.
About Novotech
Novotech is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit
https://novotech-cro.com/contact
Media Contact
David James
E:
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Source: Novotech Health Holdings Pte Ltd
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
DOCOMO and NTT Com Jointly Demonstrate Practicality of DOCOMO's New Multi-platform Cloud-rendering Technology
Jul 26, 2024 17:05 JST
TANAKA Precious Metals Provided Award Items and Ceremony Souvenirs for the International Friendly Matches of the Japan Men's National Blind Football Team at the "DAICEL Blind Football Japan Cup 2024 in Osaka" on July 7
Jul 26, 2024 03:00 JST
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
Jul 25, 2024 10:30 JST
Hitachi Awarded Largest Contract in Singapore to Supply 450 Lifts at HDB Blocks
Jul 24, 2024 16:27 JST
Hitachi to Announce Capital Reorganization of Air Conditioning Joint Venture
Jul 24, 2024 15:02 JST
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
Jul 23, 2024 20:23 JST
Toyota Material Handling Japan and Fujitsu launch Japan's first service for evaluating forklift safety in the cloud using AI
Jul 23, 2024 11:26 JST
AEON and CJPT working to resolve logistics industry issues and achieve carbon neutrality at AEON Fukuoka XD
Jul 22, 2024 13:52 JST
Rovanpera and Ogier score another TOYOTA GAZOO Racing one-two
Jul 22, 2024 12:30 JST
Team HRC with Japan Post Wins 45th Suzuka 8 Hours Endurance Road Race
Jul 22, 2024 11:33 JST
Honda to Hold its Official e-Motorsports Event, "Honda Racing eMS 2024"
Jul 19, 2024 20:04 JST
MHI America Acquires Three Utility-Scale Solar Power Projects in Pennsylvania, Advancing the Company's Energy Transition Strategy
Jul 19, 2024 19:04 JST
JCB and Worldline unveil a new whitepaper offering European merchants invaluable insights into facilitating seamless payments for international consumers
Jul 19, 2024 12:00 JST
Fujitsu Chosen to Help Solving Social Issues Caused by Fake News
Jul 19, 2024 11:30 JST
Champion REIT holds first 'ESG Week'
Jul 18, 2024 20:14 JST
Lexus LBX Adds a New High Performance Variant, the LBX "MORIZO RR"
Jul 18, 2024 17:25 JST
VitalLife and Bumrungrad International Hospital in Thailand Launch NEC's FonesVisuas Test: First Major Deployment Outside Japan, Revolutionizing Disease Risk Prediction
Jul 18, 2024 15:34 JST
Fujitsu publishes CHRO Roundtable Report 2024, summarizing the challenges and implications of the implementation of data-driven human capital management
Jul 18, 2024 10:44 JST
Fujitsu-sponsored professional golfer Ayaka Furue victorious in the Amundi Evian Championship
Jul 16, 2024 23:26 JST
Neste and Mitsubishi Corporation agree on strategic partnership to develop supply chains for renewable chemicals and plastics
Jul 16, 2024 18:36 JST
More Latest Release >>
Related Release
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
February 15 2023 09:00 JST
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
February 10 2023 19:00 JST
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
February 03 2023 13:00 JST
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
January 12 2023 15:00 JST
Novotech Acquires European CRO, Strengthens Global Operations
January 12 2023 15:00 JST
Novotech is Gold Sponsor at Biotech Showcase 2023
December 20 2022 11:00 JST
Data Shows 50% of New Trials Have Sites in Asia Pacific
December 15 2022 10:00 JST
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
December 06 2022 11:00 JST
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
November 11 2022 17:00 JST
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
October 25 2022 18:00 JST
More Press release >>